Celularity Inc. (NASDAQ:CELUW) Short Interest Down 12.5% in January
Celularity Inc. (NASDAQ:CELUW) Short Interest Down 12.5% in January
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,300 shares, a decrease of 12.5% from the January 15th total of 7,200 shares. Based on an average daily volume of 14,600 shares, the short-interest ratio is currently 0.4 days.
Celularity Inc.（纳斯达克股票代码：CELUW — Get Rating）是1月份空头利率大幅下降的目标。截至1月31日，空头利率共计6,300股，较1月15日的7,200股下降了12.5％。根据14,600股的平均每日成交量，空头利率目前为0.4天。
Celularity Price Performance
Celularity 价格表现
Celularity stock remained flat at $0.10 during trading hours on Friday. Celularity has a 12-month low of $0.06 and a 12-month high of $1.99.
周五交易时段，Celularity股票持平至0.10美元。Celularity创下12个月低点0.06美元，12个月高点为1.99美元。
Celularity Company Profile
Celularity 公司简介
(Get Rating)
（获取评分）
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc是一家临床阶段的生物技术公司，开发现成的胎盘衍生异体细胞疗法，用于治疗癌症、免疫和传染病。它通过三个部分运作：细胞疗法、退行性疾病和生物银行。该公司的主要治疗项目包括 CYCART-19，一种胎盘衍生的 CAR-T 疗法，目前处于治疗 B 细胞恶性肿瘤的 I 期临床试验中；CYNK-001，胎盘衍生的未修饰自然杀伤细胞 (NK) 细胞，正在进行治疗急性髓系白血病的 I 期临床试验，以及治疗多形性胶质母细胞瘤和 COVID-19 的 I 期临床试验；CYNK-101 转基因 NK 细胞，正在进行治疗 HER2+ 胃癌和胃食管癌的 I 期临床试验；APPL-001，胎盘-衍生的间充质样粘附基质细胞，处于治疗克罗恩病的临床前阶段；以及 PDA-002，一种胎盘衍生的间充质样粘附基质细胞，处于治疗面部肩胛肌营养不良症的临床前阶段。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- Deere Stock Raises Outlook and is Ready to Power Higher
- DraftKings Crowning Achievement: Leverage
- Tesla Stock Comeback Is Picking Up Steam
- How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
- 3 Top-Performing Energy MLPs Deliver Price Gains, High Yield
- 免费获取 StockNews.com 关于 Celularity (CELUW) 的研究报告
- 迪尔股票提高了前景并准备走高
- DraftKings 的最高成就：杠杆
- 特斯拉股票卷土重来势头强劲
- 雅培实验室、艾伯维如何从缉获药物配方中获利
- 3 家表现最佳的能源 MLP 带来价格上涨和高收益
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Celularity Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Celularity及相关公司的最新新闻和分析师评级的简明每日摘要。